Olmutinib | B1218

Olmutinib (BI 1482694), is a third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). It inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR. It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy.

Olmutinib (BI 1482694), is a third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). It inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR. It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy.

B1218 | Olmutinib DataSheet

Alternate Name/Synonyms: N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; BI1482694

Appearance: Pale yellow solid

Formulation: N/A

CAS Number: 1353550-13-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₆H₂₆N₆O₂S

Molecular Weight: 486.59

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO(>40 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI)

MDL Number: N/A

PubChem CID: 54758501

SMILES: CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)SC=C4

InChi: InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

InChi Key: FDMQDKQUTRLUBU-UHFFFAOYSA-N